• Vaccine Name: GamTBvac
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: GamTBvac contains ESAT6, CFP10, and Ag85A Mycobacterium tuberculosis (Tkachuk et al., 2020)
• FbpA (Ag85A) gene engineering:
  • Type: Fusion protein
  • Description: This is us in fusion protein preparation (Tkachuk et al., 2020).
  • Detailed Gene Information: Click Here.
• EsxA (ESAT-6) gene engineering:
  • Type: Recombinant protein preparation
  • Description: Use in fusion protein prepsrsption (Tkachuk et al., 2020).
  • Detailed Gene Information: Click Here.
• EsxB gene engineering:
  • Type: Fusion Protein
  • Description: This is use in fusion protein preparation(Tkachuk et al., 2020).
  • Detailed Gene Information: Click Here.
• Adjuvant: CpG DNA vaccine adjuvant
  • Adjuvant name: CpG DNA vaccine adjuvant
  • VO adjuvant ID: VO_0001237
  • Description: CpG adjuvant and dextran are used to help stimulate and strengthen the immune response (Tkachuk et al., 2020).
• Preparation: GamTBvac is made of two combined (fusion) tuberculosis proteins mixed with a dextran-based adjuvant and CpG to help stimulate the immune system, and it is prepared as a liquid injection given under the skin (Verreck et al., 2001).
• Immunization Route: subcutaneous injection
• Description: GamTBvac is a recombinant fusion protein tuberculosis vaccine containing Ag85A, ESAT-6, and CFP10, formulated with CpG and a dextran-based adjuvant system, and designed as a BCG booster (Tkachuk et al., 2020).

Human Response

• Vaccination Protocol: Participants received two subcutaneous injections of GamTBvac (0.5 mL each) administered eight weeks apart (Day 0 and Day 57) (Tkachuk et al., 2020).
• Immune Response: GamTBvac induced significant IFN-? release, increased Th1 cytokine-expressing CD4? T cells, and strong antigen-specific IgG antibody responses (Tkachuk et al., 2020).